On September 30, Glonhui announced that Chongqing Lummy Pharmaceutical (300006.SZ) recently received the cephalosporin cefoperazone sodium dry suspension (50mg) "Supplementary Drug Application Approval Notice" issued by the National Medical Products Administration, approving the transfer of the marketing authorization holder from "Chongqing Kerui Pharmaceutical (Group) Co., Ltd. (Address: No. 2, Dashizhi Road, Nanan Economic and Technological Development Zone, Chongqing)" to "Chongqing Lummy Pharmaceutical Co., Ltd. (Address: No. 99 Yuma Road, Nanan District, Chongqing)", with the drug approval number remaining the same. The production site, prescription, production process, quality standards, etc. of the transferred drug remain unchanged from the original drug. If the transferred drug meets the requirements for product release after passing the compliance inspection of drug production quality management norms, it can be marketed for sale.
莱美药业(300006.SZ)：获得药品补充申请批准通知书
Chongqing Lummy Pharmaceutical (300006.SZ): Received approval notice for supplementary pharmaceutical application.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.